Literature DB >> 17709531

SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection.

Ricardo Silvestre1, Anabela Cordeiro-Da-Silva, Nuno Santarém, Baptiste Vergnes, Denis Sereno, Ali Ouaissi.   

Abstract

The ability to manipulate the Leishmania genome to create genetically modified parasites by introducing or eliminating genes is considered a powerful alternative for developing a new generation vaccine against leishmaniasis. Previously, we showed that the deletion of one allele of the Leishmania infantum silent information regulatory 2 (LiSIR2) locus was sufficient to dramatically affect amastigote axenic proliferation. Furthermore, LiSIR2 single knockout (LiSIR2(+/-)) amastigotes were unable to replicate in vitro inside macrophages. Because this L. infantum mutant persisted in BALB/c mice for up to 6 wk but failed to establish an infection, we tested its ability to provide protection toward a virulent L. infantum challenge. Strikingly, vaccination with a single i.p. injection of LiSIR2(+/-) single knockout elicits complete protection. Thus, vaccinated BALB/c mice showed a reversal of T cell anergy with specific anti-Leishmania cytotoxic activity and high levels of NO production. Moreover, vaccinated mice simultaneously generated specific anti-Leishmania IgG Ab subclasses suggestive of both type 1 and type 2 responses. A strong correlation was found between the elimination of the parasites and an increased Leishmania-specific IFN-gamma/IL-10 ratio. Therefore, we propose that the polarization to a high IFN-gamma/low IL-10 ratio after challenge is a clear indicator of vaccine success. Furthermore these mutants, which presented attenuated virulence, represent a good model to understand the correlatives of protection in visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709531     DOI: 10.4049/jimmunol.179.5.3161

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells.

Authors:  Subha Banerjee; June Ghosh; Subha Sen; Rajan Guha; Ranjan Dhar; Moumita Ghosh; Sanchita Datta; Bikramjit Raychaudhury; Kshudiram Naskar; Arun Kumar Haldar; C S Lal; K Pandey; V N R Das; Pradeep Das; Syamal Roy
Journal:  Infect Immun       Date:  2009-03-16       Impact factor: 3.441

2.  Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae.

Authors:  Amir Mizbani; Yasaman Taslimi; Farnaz Zahedifard; Tahereh Taheri; Sima Rafati
Journal:  Parasitol Res       Date:  2011-03-26       Impact factor: 2.289

Review 3.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

4.  Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.

Authors:  Beatriz Coutinho De Oliveira; Malcolm S Duthie; Valéria Rêgo Alves Pereira
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

5.  Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum.

Authors:  Audrey Romano; Nicole A Doria; Jonatan Mendez; David L Sacks; Nathan C Peters
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

6.  Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis.

Authors:  Kevin W Bruhn; Ron Birnbaum; Jacquelyn Haskell; Veena Vanchinathan; Stephanie Greger; Rupa Narayan; Pei-Lin Chang; Thu Anh Tran; Suzanne M Hickerson; Stephen M Beverley; Mary E Wilson; Noah Craft
Journal:  Clin Vaccine Immunol       Date:  2012-02-08

7.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

8.  Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Authors:  Ranadhir Dey; Pradeep K Dagur; Angamuthu Selvapandiyan; J Philip McCoy; Poonam Salotra; Robert Duncan; Hira L Nakhasi
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

9.  A Leishmania-specific gene upregulated at the amastigote stage is crucial for parasite survival.

Authors:  Kumar Avishek; Kavita Ahuja; Dibyabhaba Pradhan; Sreenivas Gannavaram; Angamuthu Selvapandiyan; Hira L Nakhasi; Poonam Salotra
Journal:  Parasitol Res       Date:  2018-08-14       Impact factor: 2.289

10.  Characterization of the biology and infectivity of Leishmania infantum viscerotropic and dermotropic strains isolated from HIV+ and HIV- patients in the murine model of visceral leishmaniasis.

Authors:  Joana Cunha; Eugenia Carrillo; Carmen Sánchez; Israel Cruz; Javier Moreno; Anabela Cordeiro-da-Silva
Journal:  Parasit Vectors       Date:  2013-04-26       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.